XBP1 and metabolic dysfunction-associated steatohepatitis: Second, intravenously administrated FT@XBP1 exerted its effect mainly by targeting the key transcription factor XBP1s, however, whether it affects the integrity of the intestinal mucosal barrier and regulates liver inflammation to indirectly restore intestinal microflora homeostasis in NASH is worthy of further study.